BioSig: A Pioneer in Signal Processing Solutions
At BioSig, we're working to develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System.
We built BioSig to achieve this vision – with a strong commitment to research, a world-class leadership team, and a network of expert partners. We are now achieving important milestones as we prepare to enter the fast-growing electrophysiology market, but our aspirations reach even further: to lead one of the most innovative and most promising frontiers in healthcare.
Our Path from Research to Growth
Since our founding in 2009, BioSig has built an impressive scientific and business track record. In less than 10 years, we have developed a first-of-its-kind technology, attracted significant investment, conducted pre-clinical studies with centers of excellence, signed a 10-year strategic agreement with Mayo Clinic, and developed a robust IP strategy.
We are now poised to commercialize our first product: the PURE EP™ System. In 2018, we received FDA 510(k) clearance for PURE EP™ and began first-in-human trials, and BioSig was uplisted to the NASDAQ national exchange. In 2019, we plan to introduce PURE EP™ to medical centers nationwide, collect our first revenues, and further develop our IP and R&D. Looking further ahead, we expect to publish trial results, grow internationally, and expand our product pipeline.
Tapping the Fast-Growing EP Market
Initially, we are targeting the $4.6 billion electrophysiology (EP) market, which is growing at more than 10% annually and expected to exceed $8.5 billion by 2024. Ultimately, we hope to expand the applications of our technology to new disease areas and markets - helping to bring the promise of bioelectronic medicine to millions of patients worldwide.
Building for the Long Term
We are building BioSig for long-term impact and growth. This intent guides every decision we've made: from our culture and team to our financing and research. Our goal is nothing less than to transform the treatment of the most challenging diseases today.
To achieve this goal, we have created a culture that values the highest quality work, thorough research and scientific expertise, and deep collaboration with leaders in our field. Our exceptional culture and ambitious vision are already attracting high-powered new hires and partners for the next stage of our growth.
BioSig in the News
Journalists and analysts are beginning to notice BioSig. In 2018, we were named as one of the "50 Innovative Companies to Watch" by The Silicon Review, added to the LD Micro Index, and covered by EP Lab Digest, The Los Angeles Business Journal, Diagnostic and Interventional Cardiology, and other publications.